DBV Technologies | DBVT - Ordinary Share Capital


DBV Technologies reported $11.65M in Ordinary Share Capital for its fiscal quarter ending in March of 2025.





Ordinary Share Capital Change Date
Acadia Pharmaceuticals USD 168.71M 104K Sep/2025
Alnylam Pharmaceuticals USD 131.79M 130.49M Sep/2025
Amarin USD 20.8M 28K Sep/2025
BioMarin Pharmaceutical USD 192.1M 97K Sep/2025
DBV Technologies USD 11.65M 1000 Mar/2025
Halozyme Therapeutics USD 117.52M 98K Sep/2025
Incyte USD 196.13M 2.01M Sep/2025
Insmed USD 212.58M 210.76M Sep/2025
Ionis Pharmaceuticals USD 161.14M 160.98M Sep/2025
Neurocrine Biosciences USD 99.7M 700K Sep/2025
PTC Therapeutics USD 79.93M 554K Sep/2025
Sarepta Therapeutics USD 104.77M 7.06M Sep/2025
Ultragenyx Pharmaceutical USD 96.44M 88K Sep/2025
United Therapeutics USD 42.9M 42.1M Sep/2025